Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Aug 1;28(8):1832-1835.
doi: 10.1093/annonc/mdx266.

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

H R Ali  1   2 , A Dariush  3 , J Thomas  4 , E Provenzano  5   6   7 , J Dunn  8 , L Hiller  8 , A-L Vallier  5   7 , J Abraham  5   7 , T Piper  4 , J M S Bartlett  4   9 , D A Cameron  4 , L Hayward  4 , J D Brenton  1   5   7 , P D P Pharoah  5   7 , M J Irwin  3 , N A Walton  3 , H M Earl  5   7 , C Caldas  1   5   7
Affiliations
Clinical Trial

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

H R Ali et al. Ann Oncol. .

Abstract

Background: We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding in independent studies, among patients receiving different chemotherapy, is unknown.

Patients and methods: The ARTemis trial randomly assigned 800 women with early stage breast cancer between May 2009 and January 2013 to three cycles of docetaxel, followed by three cycles of fluorouracil, epirubicin and cyclophosphamide once every 21 days with or without four cycles of bevacizumab. The primary endpoint was pCR (absence of invasive cancer in the breast and lymph nodes). We quantified lymphocyte density within haematoxylin and eosin (H&E) whole slide images using our previously described computational pathology approach: for every detected lymphocyte the average distance to the nearest 50 lymphocytes was calculated and the density derived from this statistic. We analyzed both pre-treatment biopsies and post-treatment surgical samples of the tumour bed.

Results: Of the 781 patients originally included in the primary endpoint analysis of the trial, 609 (78%) were included for baseline lymphocyte density analyses and a subset of 383 (49% of 781) for analyses of change in lymphocyte density. The main reason for loss of patients was the availability of digitized whole slide images. Pre-treatment lymphocyte density modelled as a continuous variable was associated with pCR on univariate analysis (odds ratio [OR], 2.92; 95% CI, 1.78-4.85; P < 0.001) and after adjustment for clinical covariates (OR, 2.13; 95% CI, 1.24-3.67; P = 0.006). Increased pre- to post-treatment lymphocyte density showed an independent inverse association with pCR (adjusted OR, 0.1; 95% CI, 0.033-0.31; P < 0.001).

Conclusions: Lymphocyte density in pre-treatment biopsies was validated as an independent predictor of pCR in breast cancer. Computational pathology is emerging as a viable and objective means of identifying predictive biomarkers for cancer patients.

Clinicaltrials.gov: NCT01093235.

Keywords: breast cancer; computational pathology; neoadjuvant chemotherapy; predictive; tumour-infiltrating lymphocytes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of patients and samples through analytic stages.
Figure 2.
Figure 2.
Association between lymphocyte density, change in lymphocyte density, cellular proportions and chemotherapy response. Observations are ranked by pre-treatment lymphocyte density scores. Lymphocyte density has been rescaled to between zero and one for illustration. a.u., arbitrary units; pCR, pathological complete response; RD, residual disease.
See this image and copyright information in PMC

References

    1. Ingold Heppner B, Loibl S, Denkert C.. Tumor-infiltrating lymphocytes: a promising biomarker in breast cancer. Breast Care (Basel) 2016; 11(2): 96–100. - PMC - PubMed
    1. Earl HM, Vallier AL, Hiller L. et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol 2014; 15(2): 201–212. - PubMed
    1. Ali HR, Dariush A, Provenzano E. et al. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res 2016; 18(1): 21.. - PMC - PubMed
    1. Earl HM, Hiller L, Dunn JA. et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16(6): 656–666. - PubMed
    1. Earl HM, Hiller L, Dunn JA. et al. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. Ann Oncol 2017; 28(8): 1817–1824. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts

Associated data